Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
Running, not enrolling · Phase 4 · Has a placebo group
Conditions studied: Meniere Disease, Allergic Rhinitis, Vertigo
In brief
The purpose of this study is to evaluate a previously FDA-approved medication that is known to help with allergy symptoms to see if it can decrease symptoms in patients with Meniere's Disease.
Key facts
- Study ID
- NCT04815187
- Run by
- House Ear Institute
- People needed
- 39
- Starts
- 2021-06-07
- Expected to finish
- 2025-12-31
- Last updated by the study team
- 2025-03-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adults 18 years of age or older
- Must meet all AAO-HNS 2020 criteria for definite or probable Meniere's Disease
- Must have a skin test positive for allergy
- Is already a candidate for treatment with montelukast for allergic rhinitis/failed first line over-the-counter allergy treatments
You may not qualify if…
- Had a previous surgical procedure for treatment of vertigo
- Currently receiving any allergy immunotherapy or taking montelukast or a beta-blocker
- Pregnant or recent pregnancy ((≤ 8 weeks postpartum), or lactation)
- Current hospitalization for any reason
- Any active, acute, or chronic pulmonary disorder other than asthma
- History of intubation for asthma
Where it is running
- House Ear Clinic — Los Angeles, California, United States
- House Institute Foundation — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.